In addition, chemotherapy is the mainstay of treatment for triple-negative breast cancers (TNBCs), which do not express the estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2). This evidence concerns the gene ESR1 and triple-negative breast carcinoma.